Allergan renews its battle against an unsolicited, $53 billion takeover bid by Valeant Pharmaceuticals and hedge fund ally Pershing Square Capital Management, calling for more transparency about Valeant's business.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1yh3cHL
Cap comentari:
Publica un comentari a l'entrada